These results confirm that the cardiovascular protection seen with injectable GLP-1 agonists extends to the oral formulation, an important finding that strengthens the case for offering patients a choice of delivery method based on their preferences rather than effectiveness alone
Psychopharmacology, 214(2), 515-523
Moreover, the degree and trajectory of weight loss may have differed substantially between semaglutide users and controls, particularly if weight loss in the control group was achieved through lifestyle-related approaches rather than pharmacologic treatment, but these differences could not be measured within TriNetX
Beyond weight loss The authors say these findings could have far-reaching implications for how semaglutide and similar GLP-1 drugs should be used
Willow offers an affordable, all-inclusive plan that puts you at the center
Menor riesgo cardiovascular Semaglutida reduce las muertes por eventos cardiovasculares entre 15 % y 19 %